After much anticipation from investors, industry peers and supporters, and following on from the demand and success of Performance Fund 1, DMCC Holdings is pleased to announce the launch of DMCC Performance Fund 2. The next Mutual Fund Trust in the Performance Fund series.
Past Success
Launched in late 2018, Performance Fund 1 was released as DMCC Holdings’ first regulated offering, that presented an opportunity to invest in the stable and booming commercial real estate in the United States. As a regulated offering, the Fund had oversight from the Ontario Securities Commission as well as the Securities and Exchange Commission in the United States. Along with its competitive returns, the Fund enjoyed support from individual and institutional investors.
DMCC Performance Fund 2
The Performance Fund 2 aims to set a new benchmark of wealth creation in an increasingly competitive industry and era of unprecedented events. By focusing on a target asset mix of healthy medical real estate assets and unique retail and office deals, the fund exploits a conservative approach to capital allocation.
DMCC’s investors can expect attractive annual returns, with the same level of care and service that we are known for. The Performance Fund 2 pays out 7%* annual dividends on a quarterly basis, along with a one-time projected capital appreciation of up to 40%* upon the maturity of the investment at the end of Year 5.
Investment Details
Issuer | DMCC Performance 2, Trust |
Fund Type | US Dollar Trust |
Offering Structure | Mutual Fund Trust Units |
Minimum Investment | $5000 (50 Units) |
Transfer Agent | Computershare Investor Services Inc. |
Canadian Placement Agent | Meadowbank Asset Management Inc. |
Investment Type | Cash, RRSP, TFSA, RESP, LIRA, RRIF |
Cash Flow | 7% Y1-Y5 Dividend (paid quarterly) |
Profit Sharing | Up to 40% uplift on principal investment at Y5 end |
Redemptions | Investors may redeem units at anytime, subject to certain restrictions as set out in the Offering Memorandum |
Investors who wish to take advantage of our superb line of investment offerings can do so by getting in touch with our Investor Relations team.